Phase 3 Readout~month

Phase 3 Topline: A Multicenter, Open-label, Randomized Phase 3 Study of THIO Sequenced With Cemiplimab (LIBTAYO®) vs

Drug
thio
Indication
Carcinoma, Non-Small -Cell Lung

Other upcoming events for MAIA

Patent ExpiryPatent/Exclusivity Expiry: CUBICIN
Patent ExpiryPatent/Exclusivity Expiry: THYQUIDITY
Patent ExpiryPatent/Exclusivity Expiry: ERMEZA
Patent ExpiryPatent/Exclusivity Expiry: OLPRUVA
Patent ExpiryPatent/Exclusivity Expiry: LEVOTHYROXINE SODIUM

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Multicenter, Open-label, Randomized Phase 3 Study of THIO Sequenced With Cemiplimab (LIBTAYO®) vs — MAIA Phase 3 Readout | BioSniper